Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

11 items

Cytogenetic analysis (karyotyping) for all new diagnoses of MDS, MPN, or MDS/MPN in line with established criteria.

Funded Biomarker Disease Site: Hematology

Biomarker: TBC

Testing Method:Cytogenetics (Karyotyping)

Testing Site: Children's Hospital of Eastern Ontario (CHEO), Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Trillium Health Partners, University Health Network

FISH analysis in cases of MDS, MPN, MDS/MPN where karyotyping is insufficient or criteria for additional testing is met.

Funded Biomarker Disease Site: Hematology

Biomarker: TBC

Testing Method:Fluoroscence In Situ Hybridization (FISH)

Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.

Funded Biomarker Disease Site: Ovary

Biomarker: p53, WT1

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on all newly diagnosed breast cancers.

Funded Biomarker Disease Site: Breast

Biomarker: HER2, ER, PR

Testing Method:Immunohistochemistry (IHC)

Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Reflex testing on all newly diagnosed breast cancers.

Funded Biomarker Disease Site: Breast

Biomarker: HER2

Testing Method:In Situ Hybridization (ISH)

Reflex testing on all newly diagnosed ductal carcinoma in situ (DCIS).

Funded Biomarker Disease Site: Breast

Biomarker: ER

Testing Method:Immunohistochemistry (IHC)

Reflex testing on newly diagnosed tumours with invasive biliary/gallbladder adenocarcinoma.

Funded Biomarker Disease Site: Hepatobiliary

Biomarker: MLH1, MSH2, MSH6, PMS2

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with invasive carcinoma of the pancreas.

Funded Biomarker Disease Site: Pancreas

Biomarker: MLH1, MSH2, MSH6, PMS2

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with invasive colorectal cancer.

Funded Biomarker Disease Site: Colorectal

Biomarker: MLH!, MSH2, MSH6, PMS2

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, Southlake Regional Health Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma when needed to establish subtype.

Funded Biomarker Disease Site: Endometrium

Biomarker: P53, PR, ER

Testing Method:Immunohistochemistry (IHC)

Reflex testing on newly diagnosed tumours with upper tract (ureter / renal pelvis) urothelial carcinoma.

Funded Biomarker Disease Site: Bladder/ Urothelial

Biomarker: MLH1, MSH2, MSH6, PMS2

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System